Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response letters and a 10-3 advisory committee vote in late July recommending the therapy.
Stocktwits
More News
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?
Replimune said the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV, previously known as RP1, in combination with nivolumab.
Stocktwits
Why Is FLNC Stock Down 25% After-Hours?
Fluence Energy on Wednesday reported production delays at new factories that are expected to impact its earnings through the year.
Stocktwits
JOBY Stock Pops 8% On US Infrastructure Push Ahead Of Commercial Operations Launch
Joby announced a partnership with Travis Kalanick’s Atoms on Tuesday.
Stocktwits
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug
Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea, Omeros said.
Stocktwits
Spider-Man Helps AMC Smash Its 106-Year Revenue Record — Beating 'Avengers: Endgame'
The company said more than 10.2 million moviegoers attended AMC Theatres in the U.S. and ODEON Cinemas internationally between Wednesday and Sunday.
